Table 2.
Assay results
| RDT results | |||
|---|---|---|---|
| 2 HRP2+, 1 Pf-LDH+ | 2 HRP2−, 1 Pf-LDH+ | 1 HRP2+, 1 HRP2− | |
| PCR, n (%) | 379 | 176 | 47 |
| pfhrp2+/3+ | 210 (55) | 20 (11) | 19 (41) |
| pfhrp2−/3− | 9 (2) | 114 (65) | 10 (22) |
| pfhrp2−/3+ | 7 (2) | 14 (8) | 5 (11) |
| pfhrp2+/3− | 152 (40) | 28 (16) | 12 (26) |
| HRP2 immunoassay, n (%) | 243 | 167 | 42 |
| HRP2+ | 224 (92) | 40 (24) | 30 (71) |
| HRP2− | 19 (8) | 127 (76) | 12 (29) |
| MIP, n (%) | 198 | 104 | 30 |
| pfhrp2+/3+ | 77 (39) | 5 (5) | 5 (17) |
| pfhrp2−/3− | 10 (5) | 84 (81) | 10 (33) |
| pfhrp2−/3+ | 3 (2) | 1 (1) | 4 (13) |
| pfhrp2+/3− | 108 (55) | 14 (13) | 11 (37) |
| WGS, n (%)a | 0 | 22 | 0 |
| pfhrp2+/3+ | NA | 0 (0) | NA |
| pfhrp2−/3− | NA | 22 (100) | NA |
| pfhrp2−/3+ | NA | 0 (0) | NA |
| pfhrp2+/3− | NA | 0 (0) | NA |
PCR, bead-based antigen immunoassay, MIP deep sequencing and WGS for samples P. falciparum-positive by RDT are shown.
aZero median WGS coverage across 1,000 bp windows encompassing pfhrp2 or pfhrp3, in samples with clinical data. NA, not applicable.